AMT takes speedy second chance on Glybera in Europe
This article was originally published in Scrip
Amsterdam Molecular Therapeutics has requested a re-examination of the marketing authorisation approval application for its lead product, Glybera (alipogene tiparvovec), with the EMA, despite being turned down as recently as 24 June (scripintelligence.com, 24 June).
You may also be interested in...
Almirall has launched its irritable bowel syndrome drug Constella (linaclotide) in six European countries, with several other launches planned for later this year.
Dermira, a dermatology-focused biotech, has raised $35m in a series B financing.
Clovis Oncology has raised its public offering, announced 11 June, from $170m to $240m.